Navigation Links
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
Date:5/8/2009

EMERYVILLE, Calif., May 8 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced financial results for the three-month and nine-month periods ended March 31, 2009.

Revenues for the third quarter of fiscal 2009 were $3.0 million compared to $3.7 million for the third quarter of fiscal 2008. Research and development expenses were $1.9 million for the three months ended March 31, 2009 compared to $5.9 million for the three months ended March 31, 2008. The lower research and development expenses for the 2009 quarter were primarily due to the termination of the Viprinex(TM) program for stroke following the interim analysis in December 2008. General and administrative expenses were $1.4 million for the three months ended March 31, 2009 compared to $1.8 million for the three months ended March 31, 2008. During the third quarter of fiscal 2009, the Company terminated the employment of approximately 75% of its workforce, and the employee termination costs are included in the operating expenses for the 2009 period.

The net loss for the third quarter of fiscal 2009 was $0.4 million, or $0.02 per share, compared to a net loss of $5.1 million, or $0.19 per share, for the third quarter of fiscal 2008.

Revenues for the first nine months of fiscal 2009 were $10.1 million compared to revenues of $11.2 million for the same period of fiscal 2008. Research and development expenses were $17.7 million for the nine months ended March 31, 2009 compared to $18.8 million for the nine months ended March 31, 2008. General and administrative expenses were $4.0 million for the nine months ended March 31, 2009 compared to $5.3 million for the nine months ended March 31, 2008. The net loss for the nine months ended March 31, 2009 was $11.0 million, or $0.41 per share, compared to a net loss of $12.9 million, or $0.76 per share, for the nine months ended March 31, 2008.

Cash, cash equivalents and investments were $28.8 million at March 31, 2009. The cash and total investments balance included cash, cash equivalents and short-term investments of $21.6 million and long-term auction-rate securities carried at an estimated value of $7.2 million and classified as long-term investments. Total liabilities, excluding deferred revenue of $14.7 million and a warrant liability of $0.2 million, were $6.4 million at March 31, 2009.

"During the third quarter of fiscal 2009, we wound-down most of our operations and significantly reduced expenses. We also initiated a process to identify and evaluate alternatives for the Company's future. Our board's stated mandate in looking at these strategic alternatives is to maximize the value of our cash and other assets for the benefit of all our shareholders, and to proceed expeditiously in the process," stated William Fletcher, acting Chief Executive Officer.

Assuming accrued costs associated with the Viprinex program are fully paid off by June 30, 2009 as currently estimated, the Company expects to end its fiscal year with approximately $23 million in cash, short-term and long-term investments.

-Tables to follow -

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials as a potential new drug to treat acute ischemic stroke. NTI has more recently chosen not to extend its early-stage research programs for Huntington's and Alzheimer's diseases. NTI has rights to receive payments from an approved drug for Alzheimer's disease and an investigational drug which has recently completed a Phase 3 trial for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to our terminated clinical trials, our remaining contractual commitments, the success of our efforts to maximize the value of our cash and other assets for our shareholders, and levels of future operations and expenditures, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.

                               CONDENSED STATEMENTS OF OPERATIONS
                      (Unaudited - in thousands, except per share amounts)


                               Three months ended       Nine months ended
                                    March 31,                March 31,
                                2009        2008         2009        2008

     REVENUES
         Royalty                1,505       2,161        5,590        6,245
         Technology sale
          and collaboration
          services              1,508       1,523        4,479        5,002

     Total revenues             3,013       3,684       10,069       11,247

     EXPENSES
         Research and
          development           1,857       5,945       17,701       18,822
         General and
          administrative        1,438       1,757        3,970        5,327

           Total expenses       3,295       7,702       21,671       24,149

     Operating loss              (282)     (4,018 )    (11,602)     (12,902)
     Interest income              136         540          649        1,020
     Gain on sale of
      long-term investment          -           -          170            -
     Impairment charge for
      decrease in value of
      investments                 (55)     (1,778)         (55)      (1,778)
     Interest expense,
      including non-cash
      amortization of $2,336
      discount on notes for
      the nine months ended
      March 31, 2008                -           -            -       (2,479)
     Non-cash (loss) gain
      on change in fair value
      of warrants                (230)        193         (193)       3,271

     NET LOSS                   $(431)    $(5,063)    $(11,031)    $(12,868)

     BASIC AND DILUTED NET
      LOSS PER SHARE           $(0.02)     $(0.19)      $(0.41)      $(0.76)

     Shares used in basic
      and diluted net loss
      per share calculation    26,927      26,913       26,925       16,963



                            SELECTED BALANCE SHEET DATA
                                 (in thousands)

                                       March 31, 2008        June 30, 2008
                                         (unaudited)           (Note 1)

      Cash and cash equivalents             $6,009             $27,941
      Short-term investments                15,592               2,039
      Long-term investments                  7,202              11,850
      Total assets                          29,317              43,187
      Current liabilities                   12,102               9,042
      Total liabilities                     21,269              22,901
      Stockholders' equity                   8,048              20,286

     (1) Derived from audited financial statements.




'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
2. Neurobiological Technologies Reports Second Quarter Financial Results
3. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. Neurobiological Technologies Reports Going Concern Qualification
8. Steven H. Kane Appointed as President and Chief Executive Officer of Patient Safety Technologies, Inc.
9. Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009
10. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
11. Greenway Medical Technologies PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology: